Inflammation and depression: A study protocol to dissect pathogenetic mechanisms in the onset, comorbidity and treatment response

About one third of patients suffering from Major Depressive Disorder (MDD) do not respond to any antidepressant medications and 75% experience relapses and general health deterioration. Importantly, inflammation can contribute to such negative outcomes, as well as to cause depression in patients who have been exposed to adverse childhood experiences and/or to viral infections, including COVID-19. Depressed patients also have an increased risk for developing comorbidities, such as cardio-metabolic dysfunctions, where inflammatory alterations, again, play a role in connecting MDD and these comorbid conditions. Here, we present our study protocol funded by the Italian Ministry of Health in the context of the PNRR call (M6/C2_CALL 2022; Project code: PNRR-MAD-2022-12375859). The project aims to clarify the role of inflammation: i) in the onset of depression in association with environmental factors; ii) in the mechanisms associated with treatment response/resistance; iii) in depression and its comorbidity. To reach all these aims, we will perform biochemical, transcriptomic, genetic variants analyses on inflammatory/immune genes, pharmacokinetics and machine learning techniques, taking advantage of different human cohorts (adolescent depressed patients exposed to childhood trauma; adult depressed patients; treatment resistant depression patients; both prevalent and incident depression cases identified within a large population cohort). Moreover, we will use <i>in vitro</i> models (primary cultures of astrocytes, neurons and microglia) treated with pro-inflammatory or stressful challenges and preventive compounds to clarify the underlying mechanisms. This 2-years project will increase the knowledge on the role of inflammation in the prevention and treatment of MDD and in comorbid disorders, and it will also provide experimental evidence for the development of novel targets and tools for innovative personalized intervention strategies.

Authors

Institutions

Publication Details

Journal
Brain Behavior & Immunity - Health
Published
2024-10-05
DOI
https://doi.org/10.1016/j.bbih.2024.100886
Primary Topic
Tryptophan and brain disorders
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Inflammation and depression: A study protocol to dissect pathogenetic mechanisms in the onset, comorbidity and treatment response

Erika Vitali, Massimo Gennarelli, Nadia Cattane, Licia Iacoviello et al.
Brain Behavior & Immunity - Health
Tryptophan and brain disorders
article

Inflammation and depression: A study protocol to dissect pathogenetic mechanisms in the onset, comorbidity and treatment response

Erika Vitali, Massimo Gennarelli, Nadia Cattane, Licia Iacoviello, Francesco Benedetti, Arianna Giani, Edoardo Spina, Benedetta Vai, Annamaria Cattaneo, Catia Scassellati, Giuseppe Cicala, Alessandra Minelli, Tiziana Borsello, Alessandro Gialluisi, Patrizia Genini
article en

Abstract

About one third of patients suffering from Major Depressive Disorder (MDD) do not respond to any antidepressant medications and 75% experience relapses and general health deterioration. Importantly, inflammation can contribute to such negative outcomes, as well as to cause depression in patients who have been exposed to adverse childhood experiences and/or to viral infections, including COVID-19. Depressed patients also have an increased risk for developing comorbidities, such as cardio-metabolic dysfunctions, where inflammatory alterations, again, play a role in connecting MDD and these comorbid conditions. Here, we present our study protocol funded by the Italian Ministry of Health in the context of the PNRR call (M6/C2_CALL 2022; Project code: PNRR-MAD-2022-12375859). The project aims to clarify the role of inflammation: i) in the onset of depression in association with environmental factors; ii) in the mechanisms associated with treatment response/resistance; iii) in depression and its comorbidity. To reach all these aims, we will perform biochemical, transcriptomic, genetic variants analyses on inflammatory/immune genes, pharmacokinetics and machine learning techniques, taking advantage of different human cohorts (adolescent depressed patients exposed to childhood trauma; adult depressed patients; treatment resistant depression patients; both prevalent and incident depression cases identified within a large population cohort). Moreover, we will use <i>in vitro</i> models (primary cultures of astrocytes, neurons and microglia) treated with pro-inflammatory or stressful challenges and preventive compounds to clarify the underlying mechanisms. This 2-years project will increase the knowledge on the role of inflammation in the prevention and treatment of MDD and in comorbid disorders, and it will also provide experimental evidence for the development of novel targets and tools for innovative personalized intervention strategies.

Brain Behavior & Immunity - HealthVol. 42
University of Messina (IT), Libera Università Maria SS. Assunta (IT), Vita-Salute San Raffaele University (IT), University of Milan (IT), Mario Negri Institute for Pharmacological Research (IT), Istituto Neurologico Mediterraneo (IT), Centro San Giovanni di Dio Fatebenefratelli (IT), IRCCS Ospedale San Raffaele (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), University of Brescia (IT)
European Commission, Ministero della Salute
Good health and well-being
Openalex Percentile: Top 85%
Tryptophan and brain disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.